

10/772, 537

(FILE 'HOME' ENTERED AT 14:50:18 ON 06 JUL 2005)

FILE 'REGISTRY' ENTERED AT 14:50:33 ON 06 JUL 2005
L1 3 S HSFSGVASVE/SQSP

FILE 'CAPLUS, TOXCENTER, USPATFULL' ENTERED AT 14:51:58 ON 06 JUL 2005
L2 4 S L1
L3 2 DUP REM L2 (2 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 14:55:16 ON 06 JUL 2005

=>

L1 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN

SEQ3 1 His-Ser-Phe-Ser-Gly-Val-Ala-Ser-Val-Glu
=====

HITS AT: 1-10

RN 521914-92-1 REGISTRY

L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN

SEQ3 1 Leu-Ile-Leu-Phe-Phe-Cys-Leu-Ala-Gln-Leu-
11 Trp-Gly-Cys-Arg-Ala-Val-Pro-His-Gly-Pro-
21 Ile-Leu-Gly-Tyr-Arg-Glu-Pro-Ala-Cys-Asp-
31 Asp-Val-Glu-Thr-Glu-Gln-Ala-Ala-Leu-Ala-
41 Ala-Val-Asp-Tyr-Ile-Asn-Lys-His-Leu-Pro-
51 Arg-Gly-Tyr-Lys-His-Thr-Leu-Asn-Gln-Val-
61 Asp-Ser-Val-Lys-Val-Trp-Pro-Arg-Arg-Pro-
71 Ala-Gly-Glu-Val-Phe-Asp-Ile-Glu-Ile-Asp-
81 Thr-Leu-Glu-Thr-Thr-Cys-His-Val-Leu-Asp-
91 Pro-Thr-Pro-Leu-Ala-Asn-Cys-Ser-Val-Arg-
101 Gln-Leu-Thr-Glu-His-Ala-Val-Glu-Gly-Asp-
111 Cys-Asp-Phe-His-Val-Leu-Lys-Gln-Asp-Gly-
121 Gln-Phe-Ser-Val-Leu-Phe-Ala-Lys-Cys-Asp-
131 Ser-Ser-Pro-Asp-Ser-Ala-Glu-Asp-Val-His-
141 Lys-Val-Cys-Pro-Asn-Cys-Pro-Leu-Leu-Ala-
151 Pro-Leu-Asn-Asp-Ser-Arg-Val-Val-His-Ala-
161 Ala-Glu-Ser-Ala-Leu-Ala-Ala-Phe-Asn-Ala-
171 Gln-Ser-Asn-Gly-Ser-Tyr-Leu-Gln-Leu-Val-
181 Glu-Ile-Ser-Arg-Ala-Gln-Leu-Val-Pro-Leu-
191 Ser-Ala-Ser-Val-Ser-Val-Glu-Phe-Ala-Val-
201 Ala-Val-Thr-Asp-Cys-Val-Ala-Lys-Glu-Ala-
211 Tyr-Ser-Pro-Thr-Lys-Cys-Asn-Leu-Leu-Val-
221 Glu-Lys-Gln-Tyr-Gly-Phe-Cys-Lys-Gly-Thr-
231 Val-Thr-Ala-Lys-Val-Asn-Glu-Glu-Asp-Val-
241 Ala-Val-Thr-Cys-Thr-Val-Phe-Gln-Thr-Gln-
251 Pro-Val-Val-Leu-Gln-Pro-Gln-Pro-Ala-Gly-
261 Ala-Asp-Ala-Gly-Ala-Thr-Pro-Val-Val-Asp-
271 Ala-Ala-Ala-Thr-Ala-Ser-Pro-Leu-Ala-Asp-
281 Val-Pro-Ala-Ala-Ser-Leu-Val-Val-Gly-Pro-
291 Met-Val-Val-Ala-Val-Pro-Pro-Gly-Ile-Pro-
301 Pro-Val-His-Arg-Ser-His-Tyr-Asp-Leu-Arg-
311 His-Ser-Phe-Ser-Gly-Val-Ala-Ser-Val-Glu-
=====

321 Ser-Ala-Ser-Gly-Glu-Ala-Phe-His-Val-Gly-
331 Lys-Thr-Pro-Lys-Gly-Ala-Gln-Pro-Ser-Ile-
341 Pro-Ala-Ala-Asp-Gly-Ser-Val-Pro-Val-Val-
351 Arg-Pro-Cys-Pro-Gly-Arg-Ile-Arg-His-Phe-
361 Lys-Ile

HITS AT: 311-320

RN 481526-44-7 REGISTRY

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN

SEQ3 1 Leu-Ile-Leu-Phe-Phe-Cys-Leu-Ala-Gln-Leu-
11 Trp-Gly-Cys-Arg-Ala-Val-Pro-His-Gly-Pro-
21 Ile-Leu-Gly-Tyr-Arg-Glu-Pro-Ala-Cys-Asp-
31 Asp-Val-Glu-Thr-Glu-Gln-Ala-Ala-Leu-Ala-
41 Ala-Val-Asp-Tyr-Ile-Asn-Lys-His-Leu-Pro-
51 Arg-Gly-Tyr-Lys-His-Thr-Leu-Asn-Gln-Val-
61 Asp-Ser-Val-Lys-Val-Trp-Pro-Arg-Arg-Pro-
71 Ala-Gly-Glu-Val-Phe-Asp-Ile-Glu-Ile-Asp-
81 Thr-Leu-Glu-Thr-Thr-Cys-His-Val-Leu-Asp-
91 Pro-Thr-Pro-Leu-Ala-Asn-Cys-Ser-Val-Arg-

101 Gln-Leu-Thr-Glu-His-Ala-Val-Glu-Gly-Asp-
111 Cys-Asp-Phe-His-Val-Leu-Lys-Gln-Asp-Gly-
121 Gln-Phe-Ser-Val-Leu-Phe-Ala-Lys-Cys-Asp-
131 Ser-Ser-Pro-Asp-Ser-Ala-Glu-Asp-Val-His-
141 Lys-Val-Cys-Pro-Asn-Cys-Pro-Leu-Leu-Ala-
151 Pro-Leu-Asn-Asp-Ser-Arg-Val-Val-His-Ala-
161 Ala-Glu-Ser-Ala-Leu-Ala-Phe-Asn-Ala-
171 Gln-Ser-Asn-Gly-Ser-Tyr-Leu-Gln-Leu-Val-
181 Glu-Ile-Ser-Arg-Ala-Gln-Leu-Val-Pro-Leu-
191 Ser-Ala-Ser-Val-Ser-Val-Glu-Phe-Ala-Val-
201 Ala-Val-Thr-Asp-Cys-Val-Ala-Lys-Glu-Ala-
211 Tyr-Ser-Pro-Thr-Lys-Val-Asn-Leu-Leu-Val-
221 Glu-Lys-Gln-Tyr-Gly-Phe-Cys-Lys-Gly-Thr-
231 Val-Thr-Ala-Lys-Val-Asn-Glu-Glu-Asp-Val-
241 Ala-Val-Thr-Cys-Thr-Val-Phe-Gln-Thr-Gln-
251 Pro-Val-Val-Leu-Gln-Pro-Gln-Pro-Ala-Gly-
261 Ala-Asp-Ala-Gly-Ala-Thr-Pro-Val-Val-Asp-
271 Ala-Ala-Ala-Thr-Ala-Ser-Pro-Leu-Ala-Asp-
281 Val-Pro-Ala-Ala-Ser-Leu-Val-Val-Gly-Pro-
291 Met-Val-Val-Ala-Val-Pro-Pro-Gly-Ile-Pro-
301 Pro-Val-His-Arg-Ser-His-Tyr-Asp-Leu-Arg-
311 His-Ser-Phe-Ser-Gly-Val-Ala-Ser-Val-Glu-
=====
321 Ser-Ala-Ser-Gly-Glu-Ala-Phe-His-Val-Gly-
331 Lys-Thr-Pro-Lys-Gly-Ala-Gln-Pro-Ser-Ile-
341 Pro-Ala-Ala-Asp-Gly-Ser-Val-Pro-Val-Val-
351 Arg-Pro-Cys-Pro-Gly-Arg-Ile-Arg-His-Phe-
361 Lys-Ile

HITS AT: 311-320

RN 146706-44-7 REGISTRY

=>

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
 AN 2003:355823 CAPLUS
 DN 138:362650
 TI α 2-HS-glycoprotein for treatment of cancer and a method for preparation thereof
 IN Tsai, David
 PA USA
 SO U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 145,682.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003087809	A1	20030508	US 2002-267706	20021008
	US 5994298	A	19991130	US 1998-149878	19980908
	US 6258779	B1	20010710	US 1999-414136	19991007
	US 2001049356	A1	20011206	US 2001-902208	20010709
	US 6737402	B2	20040518		
	US 2003027767	A1	20030206	US 2002-145682	20020514
	US 6720311	B2	20040413		
	WO 2004033642	A2	20040422	WO 2003-US31706	20031007
				W: AU, CA, CN, IL, JP, KR, MX, NO, NZ, PL RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR	
PRAI	US 1997-993432	B2	19971218		
	US 1998-149878	A2	19980908		
	US 1999-414136	A2	19991007		
	US 2001-902208	A2	20010709		
	US 2002-145682	A2	20020514		
	US 2002-267706	A	20021008		

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1993:163518 CAPLUS
 DN 118:163518
 TI The nucleotide and deduced amino acid structures of sheep and pig fetuin. Common structural features of the mammalian fetuin family
 AU Brown, William M.; Dziegielewska, Katarzyna M.; Saunders, Norman R.; Christie, David L.; Nawratil, Peter; Mueller-Esterl, Werner
 CS Clin. Neurol. Sci. Group, Univ. Southampton, Southampton, SO9 4XY, UK
 SO European Journal of Biochemistry (1992), 205(1), 321-31
 CODEN: EJBCAI; ISSN: 0014-2956
 DT Journal
 LA English

=> d 1-2 hitrn

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
 IT 521914-92-1
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (amino acid sequence; α 2-HS-glycoprotein for treatment of cancer and a method for preparation thereof)

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 IT 146706-44-7
 RL: PRP (Properties)
 (amino acid sequence of, complete)

=>